European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Their entry shared how they tackle communication barriers to help healthcare teams deliver more equitable maternity care. Results due on 2 Oct.
Read more here.
With the ongoing transformation of healthcare systems, the ethical imperative to ensure fairness and equity has never been more urgent. While digital innovations offer vast potential—from telemedicine to AI-assisted diagnostics—their implementation risks exacerbating inequalities unless guided by ethical principles.
Read…
Attendees
Sponsors and Exhibitors
Contact us